Abstract:Background:The advent of immune checkpoint inhibitors (ICI) has radically changed the paradigm of care for patients with non-small cell lung cancer (NSCLC). However, response patterns of tumors treated with immunotherapies may differ compared with conventional chemotherapeutic agents or targeted therapies, and accurate assessment of the response can be radiologically challenging. Most of the current immune-related response criteria are designed to identify pseudoprogression but not hyperprogressive disease (HPD). The objective of the current analysis was to explore the biomarkers which can distinguish different patterns of responses of in ICI-treated NSCLC patients.Methods:Among patients with NSCLC treated with ICI at our Institute, at least 2 CT scans before ICI therapy (baseline and the most recent scan before baseline) and 1 CT scan during treatment were mandatory for radiological evaluation. The tumor growth rate (TGR) was calculated from the sum of the largest diameters of the target lesions as per RECIST version 1.1 to evaluate the percentage increase in tumor volume per month. HPD was defined as delta TGR exceeding 50%. Pseudoprogression was defined as initial progression, followed by complete response or partial response or stable disease. Flow cytometry was used to obtain CD3+CD8+ T cells from peripheral blood mononuclearcells. Immunosequencing of the CDR3 regions of TCRb chains was performed. TCR clonality is compared pre-therapy to initial evaluation. Results:A total of 51 patients were included in our study. By the time of first radiological assessment,11 cases were defined as Responders (21.6%), 16 patients with Stable Disease (31.4%), 24 cases defined as Progressors (47.1%).Six patients meet the criteria for HPD. During the following treatment, 3 of 24 progressors were confirmed to have pseudoprogression. The degree of TCR clonality change ranged from 2.17 to 0.64 times in all patients. Clinical response is significantly correlated with increased repertoire clonality of CD3+CD8+ T cells (P = 0.01). Among three kinds of disease progression, pseudoprogression showed an increase in TCR clonality than true progression patients (1.47 vs. 0.79, P=0.01). Interestingly, the decrease of TCR clonality is greater in patients developed typical PD than in HPD (-0.19 vs. -0.05, P=0.03). Our further analysis showed that Patients who demonstrated RECIST-PD with an increased clonality had a longer median PFS compared to patients with a declined clonality (8.9 versus 2.4 months, p = 0.01).Conclusion: The results demonstrate that the change in clonality of CD3+CD8+ T cell receptor can differentiate atypical patterns of progression in patients with NSCLC treated with ICI. Results of this TCR test performed at regular intervals during ICI treatment reflect tumor biology and have potential as a powerful biomarker to predict long-term response. Citation Format: Jiefei Han, Zhijie Wang, Yuqi Wang, Si Chen, Hua Bai, Jianchun Duan, Jie Wang. Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3247.

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

PD-1(+) IFN-gamma(+) subset of CD8(+) T cell in circulation predicts response to anti-PD-1 therapy in NSCLC

Abstract 3247: Dynamic Clonality of T Cell Receptor Differentiate Atypical Progression in NSCLC Patients Treated with PD-1/PD-L1inhibitors

Proliferation of Pd-1+Cd8 T Cells in Peripheral Blood after Pd-1-Targeted Therapy in Lung Cancer Patients

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients

Predictive Value of the Biomarker of Peripheral Blood of Lung Carcinoma Patients Responding to PD-1 Treatment: A Real-Word Study.

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma

Plasma Cytokines Interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients

Abstract PR-01: Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors